LakeShore Biopharma announced on December 12, 2024, that former chairman Yi Zhang is under investigation for misappropriating corporate assets and mismanagement, leading to significant financial losses. The company has dismissed Zhang and is actively pursuing legal actions to recover damages and restore operations while maintaining market position in the Rabies vaccine sector.